LitAlert ~~ GeneLit.com

    • Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    • Cragun D, Weidner A, Tezak A, Clouse K, Pal T.
    • Breast Cancer Res Treat. 2020 May 22. doi: 10.1007/s10549-020-05699-y. [Epub ahead of print]
    • EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    • Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM.
    • Clin Cancer Res. 2020 May 22. pii: clincanres.4121.2019. doi: 10.1158/1078-0432.CCR-19-4121. [Epub ahead of print]